An announcement from Novavax ( (NVAX) ) is now available.
On March 10, 2025, Novavax announced the resignation of James F. Young, Ph.D. from its Board of Directors, with no disagreements cited. Margaret G. McGlynn was appointed as the new Chairperson, and John W. Shiver, Ph.D. joined as a Class III director and member of the Research and Development Committee. Dr. Shiver brings over 30 years of experience in vaccine development, enhancing the board’s expertise. This transition marks a strategic shift for Novavax, as it continues to focus on partnerships and leveraging its technology platform for growth.
More about Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company focused on developing vaccines to address significant global health challenges. The company utilizes a cutting-edge technology platform, including a protein-based nanoparticle and Matrix-M™ adjuvant, to create vaccines. Novavax’s growth strategy emphasizes building partnerships through the out-licensing of its technology and vaccine assets, with a focus on infectious diseases and potential expansion into other areas.
YTD Price Performance: -4.55%
Average Trading Volume: 4,329,496
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.32B
For a thorough assessment of NVAX stock, go to TipRanks’ Stock Analysis page.